Abbott Laboratories (NYSE: ABT) is a pharmaceuticals health care company. It has 72,000 employees and operates in over 130 countries.[3] The company headquarters are in Abbott Park, North Chicago, Illinois. The company was founded by Chicago physician, Dr. Wallace Calvin Abbott in 1888. In 2008, Abbott had over $29 billion in revenue.
In 1985, the company developed the first HIV blood screening test. The company's drug portfolio includes HUMIRA, a drug for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis; Norvir, a treatment for HIV; Depakote, an anticonvulsant drug; and Synthroid, a synthetic thyroid hormone. Abbott also has a broad range of medical devices, diagnostics and immunoassay products as well as nutritional products, including Ensure, a line of well known meal replacement shakes, and EAS, the largest producer of performance based nutritional supplements.
Abbott's in vitro diagnostics business is a world leader in immunoassays and blood screening. Abbott's broad range of medical tests and diagnostic instrument systems are used worldwide by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess other important indicators of general health. Abbott Point-of-Care manufactures diagnostic products for blood analysis to provide health care professionals critical diagnostics information accurately and immediately at the point of patient care. Abbott also provides point-of-care cardiac assays to the emergency room.
Abbott Laboratories (Abbott), incorporated in 1900, is engaged in discovery, development, manufacture, and sale of a diversified line of healthcare products. The Company operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Pharmaceutical Products include a line of adult and pediatric pharmaceuticals manufactured, marketed, and sold directly to wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies and independent retailers from Abbott-owned distribution centers and public warehouses. Its Diagnostic Products include a line of diagnostic systems and tests manufactured, marketed, and sold to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, alternate-care testing sites and plasma protein therapeutic companies. The Company’s Nutritional Products include a line of pediatric and adult nutritional products manufactured, marketed and sold worldwide. Its Vascular Products include a line of coronary, endovascular, and vessel closure devices for the treatment of vascular disease manufactured, marketed and sold worldwide. On September 8, 2010, the Company acquired Piramal Healthcare Limited’s Healthcare Solutions business. In April 2010, the Company acquired Facet Biotech Corporation. In March 2010, Abbott Laboratories acquired Starlims Technologies Limited. On February 15, 2010, Abbott completed its acquisition of the Solvay Group's pharmaceuticals business.
Pharmaceutical Products
Pharmaceutical Products segment’s principal products include Humira, for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis and Crohn's disease; TriCor, Trilipix, Simcor and Niaspan, for the treatment of dyslipidemia; Kaletra, Aluvia and Norvir, protease inhibitors for the treatment of human immunodeficiency virus (HIV) infection; Synthroid, for the treatment of hypothyroidism; Lupron, also marketed as Lucrin and Lupron Depot, used for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the preoperative treatment of patients with anemia caused by uterine fibroids, and Synagis, for the treatment and prevention of respiratory syncytial virus (RSV). It also includes AndroGel, for the treatment of adult males who have low or no testosterone; the anesthesia products sevoflurane (sold in the United States under the trademark Ultane and outside of the United States primarily under the trademark Sevorane and in a few other markets as Ultane), isoflurane and enflurane; Zemplar, for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease and Stage V treatment; Synthroid, for the treatment of hypothyroidism; the anti-infective clarithromycin (sold under the trademarks Biaxin, Klacid and Klaricid), and Creon, for the treatment of pancreatic exocrine insufficiency associated with several underlying conditions, including cystic fibrosis and chronic pancreatitis.
Diagnostic Products
The Diagnostic Products segment’s principal products include immunoassay systems, including ARCHITECT, AxSYM, and ABBOTT PRISM; chemistry systems, such as ARCHITECT c4000, c8000, and c16000; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases, such as hepatitis and HIV. It also includes the m2000, an instrument that automates the extraction, purification, and preparation of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) from patient samples and detects and measures infectious agents, including HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV), and CT/NG; the Vysis product line of genomic-based tests, including the PathVysion HER-2 DNA probe kit and the UroVysion bladder cancer recurrence kit; a line of hematology systems and reagents known as the Cell-Dyn series, and the i-STAT point-of-care diagnostic systems and tests for blood analysis. In addition, under a distribution agreement with Celera Group, the Diagnostic Products segment exclusively distributes certain Celera molecular diagnostic products, including the ViroSeq HIV genotyping system and products used for the detection of mutations in the CFTR gene, which causes cystic fibrosis.
Nutritional Products
The Company’s Nutritional Products segment's products are generally marketed and sold to institutions, wholesalers, retailers, healthcare facilities, government agencies and third-party distributors from Abbott-owned distribution centers or third-party distributors. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served. Its Principal products in the Nutritional Products segment include various forms of prepared infant formula and follow-on formula, including Similac Advance, SimilacAdvance EarlyShield, Similac, Similac with Iron, Similac Sensitive, Similac Sensitive RS, Similac Go&Grow, Similac NeoSure, Similac Organic, Similac Special Care, Isomil Advance, Isomil, Isomil Go&Grow, Alimentum, Gain and Grow; adult and other pediatric nutritional products, which include Ensure, Ensure Plus, Ensure High Protein, Glucerna, ProSure, PediaSure, PediaSure NutriPals, EleCare, Juven, Abound and Pedialyte; nutritional products used in enteral feeding in healthcare institutions, including Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite, Oxepa and Nepro, and ZonePerfect bars and the EAS family of nutritional brands, including Myoplex and AdvantEdge. In addition, certain nutritional products sold as Gain, Grow, PediaSure, PediaSure NutriPals, Pedialyte, Ensure, ZonePerfect, EAS/Myoplex and Glucerna are also promoted directly to the public.
Vascular Products
The Vascular Products segment's products are generally marketed and sold directly to hospitals from Abbott-owned distribution centers and public warehouses. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served. The principal products included in the Vascular Products segment include Xience Prime and Xience V drug-eluting stent systems developed on the Multi-Link Vision platform; Multi-Link 8, Multi-Link Vision and Multi-Link Mini Vision, coronary metallic stents; TREK and Voyager balloon dilatation products; Hi-Torque Balance Middleweight Elite and Asahi coronary guidewires; StarClose and Perclose vessel closure devices; Acculink/Accunet and Xact/Emboshield NAV6 carotid stent systems; MitraClip, a percutaneous valve repair system, and ABSORB, a drug eluting bioresorbable vascular scaffold.
Other Products
The principal products in Abbott's other businesses include blood glucose monitoring meters, test strips, data management software and accessories for people with diabetes, including the FreeStyle product line, and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. These products are marketed worldwide and generally sold directly to wholesalers, government agencies, healthcare facilities, mail order pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. Some of these products are marketed and distributed through distributors. Blood glucose monitoring meters, contact lens care products, and dry eye products are also marketed and sold over-the-counter to consumers.
Principal Subsidiaries: Abbott Chemicals Plant, Inc.; Abbott Fermentation Products de Puerto Rico, Inc.; Abbott Health Products, Inc.; Abbott Home Infusion Services of New York, Inc.; Abbott International Ltd.; Abbott International Ltd. of Puerto Rico; Abbott Laboratories Inc.; Abbott Laboratories International Co.; Abbott Laboratories Pacific Ltd.; Abbott Laboratories (Puerto Rico) Incorporated; Abbott Laboratories Residential Development Fund, Inc.; Abbott Laboratories Services Corp.; Abbott Trading Company, Inc.; Abbott Universal Ltd.; AC Merger Sub Inc.; CMM Transportation, Inc.; Corporate Alliance, Inc.; IMTC Technologies, Inc.; Murex Diagnostics, Inc.; North Shore Properties, Inc.; Oximetrix de Puerto Rico, Inc.; Perclose, Inc.; Solartek Products, Inc.; Sorenson Research Co., Inc.; Swan-Myers, Incorporated; TAP Finance Inc.; Tobal Products Incorporated; Abbott Laboratories Argentina, S.A.; Abbott Australasia Pty. Limited (Australia); MediSense Australia Pty. Ltd.; Abbott Gesellschaft m.b.H. (Austria); Abbott Hospitals Limited (Bahamas); Murex Diagnostics International, Inc. (Barbados); Abbott, S.A. (Belgium); Abbott Laboratorios do Brasil Ltda. (Brazil); Abbott Laboratories Limited (Canada); International Murex Technologies Corporation (Canada); Abbott Laboratories de Chile Limitada (Chile); Abbott Laboratories de Colombia, S.A.; Abbott Laboratories s.r.o. (Czech Republic); Murex Diagnostica, Spol. s.r.o. (Czech Republic); Abbott Laboratories A/S (Denmark); Murex Diagnostics A/S (Denmark); Abbott Laboratorios del Ecuador, S.A.; Abbott, S.A. de C.V. (El Salvador); Abbott OY (Finland); Abbott France S.A.; Alcyon Analyzer S.A.; MediSense France SARL; Murex Diagnostics (France) S.A.; Abbott G.m.b.H. (Germany); Abbott Diagnostics G.m.b.H. (Germany); Murex Diagnostica GmbH (Germany); Abbott Laboratories (Hellas) S.A. (Greece); Abbott Laboratorios, S.A. (Guatemala); Abbott Laboratories Limited (Hong Kong); Abbott Laboratories (Hungary) Ltd.; Abbott Laboratories (India) Ltd. (51%); Abind Healthcare Private Limited (India); P.T. Abbott Indonesia (97%); Abbott Laboratories, Ireland, Limited; Abbott Ireland Ltd.; Abbott S.p.A. (Italy); Murex Diagnostici S.p.A. (Italy); Abbott Japan K.K. (Japan); Dainabot Co., Ltd. (Japan; 73%); Abbott Korea Limited; Abbott Middle East S.A.R.L. (Lebanon); Abbott Laboratories (Malaysia) Sdn. Bhd.; Abbott Laboratories de Mexico, S.A. de C.V.; Abbott Laboratories (Mozambique) Limitada; Edisco B.V. (Netherlands); Abbott B.V. (Netherlands); Abbott Laboratories B.V. (Netherlands); Abbott Finance B.V. (Netherlands); Abbott Holdings B.V. (Netherlands); MediSense Europe B.V. (Netherlands); MediSense Netherlands, B.V.; IMTC Holdings B.V. (Netherlands); IMTC Finance B.V. (Netherlands); Murex Diagnostics Benelux B.V. (Netherlands); Abbott Laboratories (N.Z.) Limited (New Zealand); Abbott Norge A S (Norway); Abbott Laboratories (Pakistan) Limited (83.42%); Abbott Laboratories, C.A. (Panama); Abbott Overseas, S.A. (Panama); Abbott Laboratorios S.A. (Peru); Abbott Laboratories (Philippines); Abbott Laboratories Sp. z.o.o. (Poland); Abbott Laboratorios, Limitada (Portugal); Abbott Laboratories (Singapore) Private Limited; Abbott Laboratories South Africa (Pty.) Limited; Abbott Laboratories, S.A. (Spain); Abbott Cientifica, S.A. (Spain); Abbott Scandinavia A.B. (Sweden); Abbott A.G. (Switzerland); Abbott Laboratories S.A. (Switzerland); Abbott Finance Company S.A. (Switzerland); Abbott Laboratories Taiwan Limited; Abbott Laboratories Limited (Thailand); Abbott Laboratuarlari Ithalat Ihracat Ve Tecaret Limited Sirketi (Turkey); Abbott Investments Limited (U.K.); Abbott Laboratories Limited (U.K.); Abbott (UK) Holdings Limited; Abbott Laboratories Trustee Company Limited (U.K.); IMTC Holdings (UK) Limited; MediSense Britain, Ltd. (U.K.); MediSense UK Ltd.; Murex Biotech Limited (U.K.); Specialist Diagnostica Limited (U.K.); Abbott Laboratories Uruguay Limitada; Abbott Laboratories, C.A. (Venezuela); Medicamentos M & R, S.A. (Venezuela).
Principal Divisions: Pharmaceutical Products; Ross Products; Hospital Products; Abbott International; Diagnostics; Specialty Products.
Principal Competitors: Merck & Co., Inc.; Eli Lilly and Company; Pfizer Inc.; Bristol-Myers Squibb Company; American Home Products Corporation; Johnson & Johnson; AstraZeneca PLC; Aventis; Bayer AG; GlaxoSmithKline plc; Schering-Plough Corporation; Novartis AG; Roche Holding Ltd.
Chairman and CEO Miles White
Managing Director Siegfried Brune
EVP Finance and CFO Thomas Freyman
Address:
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
U.S.A.
In 1985, the company developed the first HIV blood screening test. The company's drug portfolio includes HUMIRA, a drug for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis; Norvir, a treatment for HIV; Depakote, an anticonvulsant drug; and Synthroid, a synthetic thyroid hormone. Abbott also has a broad range of medical devices, diagnostics and immunoassay products as well as nutritional products, including Ensure, a line of well known meal replacement shakes, and EAS, the largest producer of performance based nutritional supplements.
Abbott's in vitro diagnostics business is a world leader in immunoassays and blood screening. Abbott's broad range of medical tests and diagnostic instrument systems are used worldwide by hospitals, laboratories, blood banks, and physician offices to diagnose and monitor diseases such as HIV, hepatitis, cancer, heart failure and metabolic disorders, as well as assess other important indicators of general health. Abbott Point-of-Care manufactures diagnostic products for blood analysis to provide health care professionals critical diagnostics information accurately and immediately at the point of patient care. Abbott also provides point-of-care cardiac assays to the emergency room.
Abbott Laboratories (Abbott), incorporated in 1900, is engaged in discovery, development, manufacture, and sale of a diversified line of healthcare products. The Company operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Pharmaceutical Products include a line of adult and pediatric pharmaceuticals manufactured, marketed, and sold directly to wholesalers, distributors, government agencies, healthcare facilities, specialty pharmacies and independent retailers from Abbott-owned distribution centers and public warehouses. Its Diagnostic Products include a line of diagnostic systems and tests manufactured, marketed, and sold to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, alternate-care testing sites and plasma protein therapeutic companies. The Company’s Nutritional Products include a line of pediatric and adult nutritional products manufactured, marketed and sold worldwide. Its Vascular Products include a line of coronary, endovascular, and vessel closure devices for the treatment of vascular disease manufactured, marketed and sold worldwide. On September 8, 2010, the Company acquired Piramal Healthcare Limited’s Healthcare Solutions business. In April 2010, the Company acquired Facet Biotech Corporation. In March 2010, Abbott Laboratories acquired Starlims Technologies Limited. On February 15, 2010, Abbott completed its acquisition of the Solvay Group's pharmaceuticals business.
Pharmaceutical Products
Pharmaceutical Products segment’s principal products include Humira, for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis and Crohn's disease; TriCor, Trilipix, Simcor and Niaspan, for the treatment of dyslipidemia; Kaletra, Aluvia and Norvir, protease inhibitors for the treatment of human immunodeficiency virus (HIV) infection; Synthroid, for the treatment of hypothyroidism; Lupron, also marketed as Lucrin and Lupron Depot, used for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the preoperative treatment of patients with anemia caused by uterine fibroids, and Synagis, for the treatment and prevention of respiratory syncytial virus (RSV). It also includes AndroGel, for the treatment of adult males who have low or no testosterone; the anesthesia products sevoflurane (sold in the United States under the trademark Ultane and outside of the United States primarily under the trademark Sevorane and in a few other markets as Ultane), isoflurane and enflurane; Zemplar, for the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease and Stage V treatment; Synthroid, for the treatment of hypothyroidism; the anti-infective clarithromycin (sold under the trademarks Biaxin, Klacid and Klaricid), and Creon, for the treatment of pancreatic exocrine insufficiency associated with several underlying conditions, including cystic fibrosis and chronic pancreatitis.
Diagnostic Products
The Diagnostic Products segment’s principal products include immunoassay systems, including ARCHITECT, AxSYM, and ABBOTT PRISM; chemistry systems, such as ARCHITECT c4000, c8000, and c16000; assays used for screening and/or diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, physiological diseases, and infectious diseases, such as hepatitis and HIV. It also includes the m2000, an instrument that automates the extraction, purification, and preparation of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) from patient samples and detects and measures infectious agents, including HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), human papillomavirus (HPV), and CT/NG; the Vysis product line of genomic-based tests, including the PathVysion HER-2 DNA probe kit and the UroVysion bladder cancer recurrence kit; a line of hematology systems and reagents known as the Cell-Dyn series, and the i-STAT point-of-care diagnostic systems and tests for blood analysis. In addition, under a distribution agreement with Celera Group, the Diagnostic Products segment exclusively distributes certain Celera molecular diagnostic products, including the ViroSeq HIV genotyping system and products used for the detection of mutations in the CFTR gene, which causes cystic fibrosis.
Nutritional Products
The Company’s Nutritional Products segment's products are generally marketed and sold to institutions, wholesalers, retailers, healthcare facilities, government agencies and third-party distributors from Abbott-owned distribution centers or third-party distributors. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served. Its Principal products in the Nutritional Products segment include various forms of prepared infant formula and follow-on formula, including Similac Advance, SimilacAdvance EarlyShield, Similac, Similac with Iron, Similac Sensitive, Similac Sensitive RS, Similac Go&Grow, Similac NeoSure, Similac Organic, Similac Special Care, Isomil Advance, Isomil, Isomil Go&Grow, Alimentum, Gain and Grow; adult and other pediatric nutritional products, which include Ensure, Ensure Plus, Ensure High Protein, Glucerna, ProSure, PediaSure, PediaSure NutriPals, EleCare, Juven, Abound and Pedialyte; nutritional products used in enteral feeding in healthcare institutions, including Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite, Oxepa and Nepro, and ZonePerfect bars and the EAS family of nutritional brands, including Myoplex and AdvantEdge. In addition, certain nutritional products sold as Gain, Grow, PediaSure, PediaSure NutriPals, Pedialyte, Ensure, ZonePerfect, EAS/Myoplex and Glucerna are also promoted directly to the public.
Vascular Products
The Vascular Products segment's products are generally marketed and sold directly to hospitals from Abbott-owned distribution centers and public warehouses. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served. The principal products included in the Vascular Products segment include Xience Prime and Xience V drug-eluting stent systems developed on the Multi-Link Vision platform; Multi-Link 8, Multi-Link Vision and Multi-Link Mini Vision, coronary metallic stents; TREK and Voyager balloon dilatation products; Hi-Torque Balance Middleweight Elite and Asahi coronary guidewires; StarClose and Perclose vessel closure devices; Acculink/Accunet and Xact/Emboshield NAV6 carotid stent systems; MitraClip, a percutaneous valve repair system, and ABSORB, a drug eluting bioresorbable vascular scaffold.
Other Products
The principal products in Abbott's other businesses include blood glucose monitoring meters, test strips, data management software and accessories for people with diabetes, including the FreeStyle product line, and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. These products are marketed worldwide and generally sold directly to wholesalers, government agencies, healthcare facilities, mail order pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. Some of these products are marketed and distributed through distributors. Blood glucose monitoring meters, contact lens care products, and dry eye products are also marketed and sold over-the-counter to consumers.
Principal Subsidiaries: Abbott Chemicals Plant, Inc.; Abbott Fermentation Products de Puerto Rico, Inc.; Abbott Health Products, Inc.; Abbott Home Infusion Services of New York, Inc.; Abbott International Ltd.; Abbott International Ltd. of Puerto Rico; Abbott Laboratories Inc.; Abbott Laboratories International Co.; Abbott Laboratories Pacific Ltd.; Abbott Laboratories (Puerto Rico) Incorporated; Abbott Laboratories Residential Development Fund, Inc.; Abbott Laboratories Services Corp.; Abbott Trading Company, Inc.; Abbott Universal Ltd.; AC Merger Sub Inc.; CMM Transportation, Inc.; Corporate Alliance, Inc.; IMTC Technologies, Inc.; Murex Diagnostics, Inc.; North Shore Properties, Inc.; Oximetrix de Puerto Rico, Inc.; Perclose, Inc.; Solartek Products, Inc.; Sorenson Research Co., Inc.; Swan-Myers, Incorporated; TAP Finance Inc.; Tobal Products Incorporated; Abbott Laboratories Argentina, S.A.; Abbott Australasia Pty. Limited (Australia); MediSense Australia Pty. Ltd.; Abbott Gesellschaft m.b.H. (Austria); Abbott Hospitals Limited (Bahamas); Murex Diagnostics International, Inc. (Barbados); Abbott, S.A. (Belgium); Abbott Laboratorios do Brasil Ltda. (Brazil); Abbott Laboratories Limited (Canada); International Murex Technologies Corporation (Canada); Abbott Laboratories de Chile Limitada (Chile); Abbott Laboratories de Colombia, S.A.; Abbott Laboratories s.r.o. (Czech Republic); Murex Diagnostica, Spol. s.r.o. (Czech Republic); Abbott Laboratories A/S (Denmark); Murex Diagnostics A/S (Denmark); Abbott Laboratorios del Ecuador, S.A.; Abbott, S.A. de C.V. (El Salvador); Abbott OY (Finland); Abbott France S.A.; Alcyon Analyzer S.A.; MediSense France SARL; Murex Diagnostics (France) S.A.; Abbott G.m.b.H. (Germany); Abbott Diagnostics G.m.b.H. (Germany); Murex Diagnostica GmbH (Germany); Abbott Laboratories (Hellas) S.A. (Greece); Abbott Laboratorios, S.A. (Guatemala); Abbott Laboratories Limited (Hong Kong); Abbott Laboratories (Hungary) Ltd.; Abbott Laboratories (India) Ltd. (51%); Abind Healthcare Private Limited (India); P.T. Abbott Indonesia (97%); Abbott Laboratories, Ireland, Limited; Abbott Ireland Ltd.; Abbott S.p.A. (Italy); Murex Diagnostici S.p.A. (Italy); Abbott Japan K.K. (Japan); Dainabot Co., Ltd. (Japan; 73%); Abbott Korea Limited; Abbott Middle East S.A.R.L. (Lebanon); Abbott Laboratories (Malaysia) Sdn. Bhd.; Abbott Laboratories de Mexico, S.A. de C.V.; Abbott Laboratories (Mozambique) Limitada; Edisco B.V. (Netherlands); Abbott B.V. (Netherlands); Abbott Laboratories B.V. (Netherlands); Abbott Finance B.V. (Netherlands); Abbott Holdings B.V. (Netherlands); MediSense Europe B.V. (Netherlands); MediSense Netherlands, B.V.; IMTC Holdings B.V. (Netherlands); IMTC Finance B.V. (Netherlands); Murex Diagnostics Benelux B.V. (Netherlands); Abbott Laboratories (N.Z.) Limited (New Zealand); Abbott Norge A S (Norway); Abbott Laboratories (Pakistan) Limited (83.42%); Abbott Laboratories, C.A. (Panama); Abbott Overseas, S.A. (Panama); Abbott Laboratorios S.A. (Peru); Abbott Laboratories (Philippines); Abbott Laboratories Sp. z.o.o. (Poland); Abbott Laboratorios, Limitada (Portugal); Abbott Laboratories (Singapore) Private Limited; Abbott Laboratories South Africa (Pty.) Limited; Abbott Laboratories, S.A. (Spain); Abbott Cientifica, S.A. (Spain); Abbott Scandinavia A.B. (Sweden); Abbott A.G. (Switzerland); Abbott Laboratories S.A. (Switzerland); Abbott Finance Company S.A. (Switzerland); Abbott Laboratories Taiwan Limited; Abbott Laboratories Limited (Thailand); Abbott Laboratuarlari Ithalat Ihracat Ve Tecaret Limited Sirketi (Turkey); Abbott Investments Limited (U.K.); Abbott Laboratories Limited (U.K.); Abbott (UK) Holdings Limited; Abbott Laboratories Trustee Company Limited (U.K.); IMTC Holdings (UK) Limited; MediSense Britain, Ltd. (U.K.); MediSense UK Ltd.; Murex Biotech Limited (U.K.); Specialist Diagnostica Limited (U.K.); Abbott Laboratories Uruguay Limitada; Abbott Laboratories, C.A. (Venezuela); Medicamentos M & R, S.A. (Venezuela).
Principal Divisions: Pharmaceutical Products; Ross Products; Hospital Products; Abbott International; Diagnostics; Specialty Products.
Principal Competitors: Merck & Co., Inc.; Eli Lilly and Company; Pfizer Inc.; Bristol-Myers Squibb Company; American Home Products Corporation; Johnson & Johnson; AstraZeneca PLC; Aventis; Bayer AG; GlaxoSmithKline plc; Schering-Plough Corporation; Novartis AG; Roche Holding Ltd.
Chairman and CEO Miles White
Managing Director Siegfried Brune
EVP Finance and CFO Thomas Freyman
Address:
100 Abbott Park Road
Abbott Park, Illinois 60064-6400
U.S.A.